Autolus Therapeutics (AUTL) Misses Q2 EPS by 3c
Tweet
Share
E-mail
Get Alerts AUTL Hot Sheet
Join SI Premium – FREE
Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.22), $0.03 worse than the analyst estimate of ($0.19).
For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Morgan Stanley Upgrades Audinate Group Ltd (AD8:AU) to Overweight
- Morgan Stanley Starts eMemory Technology Inc (3529:TT) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
